Axibin Adverse Reactions

Cardiogenic: Cardiotoxicity may be manifested in tachycardia, including supraventricular tachycardia, arrhythmia, abdominal pain, and ECG changes. Routine ECG monitoring is recommended and caution should be exercised in patients with impaired cardiac function.
Shock: Rarely, shock may occur. Therefore, it should be sufficiently observed, if necessary, the administration should be discontinued and/or appropriate therapy instituted.
Hematologic: Anemia, bleeding, leukocytopenia, and thrombopenia.
Hypersensitivity: Fever, chills, and urticaria have been reported occasionally. Anaphylaxis may occur.
Hepatic: Hepatic impairment has been reported occasionally.
Renal: Occasionally, proteinuria has been reported.
Gastrointestinal: Acute nausea and vomiting occurs frequently and may be severe. Mucositis (stomatitis and esophagitis) may occur 5 to 10 days after administration. Anorexia and diarrhea have been occasionally reported.
Cutaneous: Reversible complete alopecia occurs in most cases. Hyperpigmentation of nailbeds and dermal creases have been reported in a few cases.
CNS: Fatigue and headache occurs frequently.
Urinary system: Cystic stimulation symptoms (oliguria, urodynia, urocystitis, hematuria) by vesicoclysis therapy.
Respiratory system: Pneumothorax during treat symptom which metastasize to the lungs.
Other: Blennophthalmia, epiphora, amenorrhea, aspermia occur.